biotech · Rheumatoid Arthritis · Pharmacokinetics · XBIT
XBiotech Germany
XBiotech Germany GmbH
XBiotech Germany clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Baesweiler, DE
- Employees
- 30
- Programs
- 8
- Drugs
- 6
- Patents
- 31
XBiotech Germany projects
8 ClinicalTrials.gov programs sponsored by XBiotech Germany.
XBiotech Germany has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
514G3 (2 mg/kg) plus standard IV antibiotic treatment
XBiotech Germany GmbH
Staphylococcus Aureus Bacteremia
1 trial -
Natrunix
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
Natrunix 400 mg
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
Natrunix with MTX placebo (+folate)
XBiotech Germany GmbH
Rheumatoid Arthritis
1 trial -
XB2001 or Placebo
XBiotech Germany GmbH
Pancreatic Cancer
1 trial -
vilamakitug
XBiotech Germany GmbH
Axial Spondyloarthritis
1 trial -
Hutrukin
XBiotech Germany GmbH
Pharmacokinetics
1 trial -
NatrunixTM
XBiotech Germany GmbH
Pharmacokinetics
1 trial
Frequently asked questions
How many clinical projects does XBiotech Germany have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.